Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study-Reference-Cited by-同舟云学术

Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study

Published:2013-02 Issue:2 Volume:24 Page:412-419
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

André T.,Blons H.,Mabro M.,Chibaudel B.,Bachet J-B.,Tournigand C.,Bennamoun M.,Artru P.,Nguyen S.,Ebenezer C.,Aissat N.,Cayre A.,Penault-Llorca F.,Laurent-Puig P.,de Gramont A.

Funder

AMGEN, GERCOR Group

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/24/2/412/13789309/mds465.pdf

Reference35 articles.

1. Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer;Winder;Gastroenterology,2010

2. Therapeutic strategy in unresectable metastatic colorectal cancer;Chibaudel;Ther Adv Med Oncol,2012

3. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer;Cunningham;N Engl J Med,2004